Advertisement TB vaccine supported by Danida grant, Medicon trial site deal - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

TB vaccine supported by Danida grant, Medicon trial site deal

In a move that makes Denmark the first European country to support the Aeras Foundation's TB vaccine development efforts, development agency Danida has committed to invest $785,000 to fund Aeras and Medicon A/S' development of a vaccine trial site in South Africa.

The Aeras Global TB Vaccine Foundation is an international non-governmental organization currently funded by the Bill & Melinda Gates Foundation and the US Centers for Disease Control and Prevention. It focuses on developing new vaccines against TB and ensuring their universal availability.

In addition to the Danida grant, Danish research company Medicon A/S has revealed that it will help build clinical research infrastructure in South Africa to pave the way for large-scale phase III TB vaccine trials in 2007.

“We are very satisfied to facilitate the participation of a leading Danish company like Medicon in a partnership with Aeras and the University of Cape Town in the fight against TB,” said Bo Jensen, head of department, business cooperation & technical assistance, Ministry of Foreign Affairs of Denmark.